Crossbow Therapeutics Launches With $80 Million In Series A Financing To Advance A Novel Class Of Antibody Therapies That Mimic T-Cell Receptors To Treat Cancer
Crossbow Therapeutics Launches With $80 Million In Series A Financing To Advance A Novel Class Of Antibody Therapies That Mimic T-Cell Receptors To Treat Cancer
07/11/23, 11:33 AM
Location
cambridgeMoney raised
$80 million
Industry
biotechnology
health care
Round Type
series a
Crossbow Therapeutics, Inc., a biotechnology company developing a novel class of potent and precise antibody therapies to treat a broad range of cancers, today announced an $80 million Series A funding round led by MPM BioImpact and Pfizer Ventures, with participation from Polaris Partners, BVF Partners, Eli Lilly and Company, Mirae Asset Venture Investment, and Mirae Asset Capital.
Company Info
Location
cambridge, maryland, united states
Additional Info
Crossbow Therapeutics, Inc., is a biotechnology company determined to improve the lives of people with cancer by unlocking the therapeutic potential of T-cell receptor (TCR)-mimetic antibodies. The company’s T-Bolt™ therapies are next-generation, easily assembled immunotherapies directed with high precision at previously unreachable cancer cell targets. Crossbow’s efficient and selective approach is designed to target the entire universe of cancer proteins, dramatically expanding the potential of antibody therapy to address many types of cancer.